WoS
🏆 JCR Q2 · JIF 3,3
YÖKSİS Eşleşti
2023 Article 10. Yazar
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
·
Cilt 149, s. 4141-4148
·
ISSN 0171-5216
Prof. Dr. ORHAN ÖNDER EREN
· 38 yazar
WoS
🏆 JCR Q2 · JIF 3,1
YÖKSİS Eşleşti
2022 Article 11. Yazar
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study
FUTURE ONCOLOGY
·
Cilt 18, s. 2573-2582
·
ISSN 1479-6694
Prof. Dr. ORHAN ÖNDER EREN
· 45 yazar